Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy

Trametinib, a selective inhibitor of mitogen‐activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression‐free survival compared with chemotherapy in patients with BRAF V600E/K mutation–positive advanced or metastatic melanoma (MM). However, the pivotal clinical trial permit...

Descripción completa

Detalles Bibliográficos
Autores principales: Latimer, Nicholas R., Bell, Helen, Abrams, Keith R., Amonkar, Mayur M., Casey, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864810/
https://www.ncbi.nlm.nih.gov/pubmed/27172483
http://dx.doi.org/10.1002/cam4.643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864810/
https://www.ncbi.nlm.nih.gov/pubmed/27172483
http://dx.doi.org/10.1002/cam4.643

Ejemplares similares